FDA Finds Potential Carcinogen In Zantac Heartburn Drug; State Class Action Filed
SAN JOSE, Calif. — On the same day the Food and Drug Administration said it found the suspected carcinogen N-nitrosodimethylamine (NDMA) in the heartburn drug Zantac, four plaintiffs filed a class...To view the full article, register now.
Already a subscriber? Click here to view full article